Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Homology Medicines Inc. FIXX

Homology Medicines Inc is a US-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic...

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:FIXX)

Fundamentals Snapshot (NDAQ:FIXX)

Current News (NDAQ:FIXX)

Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update

GlobeNewswire 5 hours ago

Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy

GlobeNewswire 4 days ago

Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver

GlobeNewswire July 5, 2022

Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU

GlobeNewswire June 29, 2022

Homology Medicines Announces FDA Lifted Clinical Hold on pheNIX Gene Therapy Trial for PKU

GlobeNewswire June 13, 2022

FIXX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 24, 2022 in the Class Action Filed on Behalf of Homology Medicines, Inc. Limited Shareholders

Newsfile May 24, 2022

SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline - FIXX

PR Newswire May 24, 2022

Homology Class Action: Levi & Korsinsky Reminds Homology Medicines, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 24, 2022 - FIXX

Newsfile May 24, 2022

FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Homology Medicines, Inc. with Losses of $100,000 to Contact the Firm

PR Newswire May 24, 2022

Opinion & Analysis (NDAQ:FIXX)

No current opinion is available.

Bullboard Posts (NDAQ:FIXX)